Bcma Car-T Cells
Relapsed/Refractory
The First Affiliated Hospital of Xiamen UniversityCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Relapsed/Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | B |
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 University Health Network, Toronto | Phase 2 | CCC |
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Pomalidomide Millennium Pharmaceuticals, Inc. | Phase 1/2 | CCC |
Mezagitamab Millennium Pharmaceuticals, Inc. | Phase 1/2 | CCC |
View all 18 →
Same molecule, other indications
Bcma Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →